[
    "COMBINATION\u00a0OF\u00a0BCL-2/BCL-XL\u00a0INHIBITORS\u00a0AND\u00a0CHEMOTHERAPEUTIC\u00a0AGENT\u00a0AND\u00a0USE\u00a0THEREOFFIELD\u00a0OF\u00a0THE\u00a0INVENTIONThe\u00a0present\u00a0disclosure\u00a0relates\u00a0to\u00a0a\u00a0pharmaceutical\u00a0composition\u00a0and\u00a0use\u00a0thereof\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0cancer,\u00a0and\u00a0a\u00a0method\u00a0of\u00a0treating\u00a0cancer\u00a0comprising\u00a0a\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0and\u00a0a\u00a0chemotherapeutic\u00a0agent.</p>BACKGROUNDApoptosis\u00a0is\u00a0a\u00a0natural\u00a0pathway\u00a0for\u00a0the\u00a0body\u00a0to\u00a0clear\u00a0abnormal\u00a0or\u00a0unwanted\u00a0cells,\u00a0and\u00a0if\u00a0it\u00a0is\u00a0affected,\u00a0it\u00a0may\u00a0lead\u00a0to\u00a0various\u00a0diseases\u00a0such\u00a0as\u00a0cancer.\u00a0Bcl-2\u00a0family\u00a0proteins\u00a0are\u00a0important\u00a0regulators\u00a0of\u00a0apoptosis.\u00a0The\u00a0family\u00a0of\u00a0proteins\u00a0includes\u00a0anti-apoptotic\u00a0proteins\u00a0such\u00a0as\u00a0Bcl-2,\u00a0Bcl-xL\u00a0and\u00a0Mcl-1;\u00a0and\u00a0pro-apoptotic\u00a0molecules,\u00a0including\u00a0Bid,\u00a0Bim,\u00a0Bad,\u00a0Bak\u00a0and\u00a0Bax.\u00a0Although\u00a0normal\u00a0cells\u00a0have\u00a0low\u00a0expression\u00a0levels\u00a0of\u00a0anti-apoptotic\u00a0Bcl-2\u00a0and\u00a0Bcl-xL\u00a0proteins,\u00a0these\u00a0proteins\u00a0are\u00a0found\u00a0to\u00a0be\u00a0highly\u00a0overexpressed\u00a0in\u00a0many\u00a0different\u00a0types\u00a0of\u00a0human\u00a0tumors\u00a0and\u00a0are\u00a0implied\u00a0in\u00a0tumor\u00a0development,\u00a0progression\u00a0and\u00a0resistance\u00a0to\u00a0drugs.\u00a0Targeting\u00a0Bcl-2\u00a0and/or\u00a0Bcl-xL\u00a0has\u00a0been\u00a0investigated\u00a0as\u00a0a\u00a0cancer\u00a0treatment\u00a0strategy.</p>The\u00a0first\u00a0generation\u00a0Bcl-2/Bcl-xL\u00a0inhibitors\u00a0ABT-737\u00a0and\u00a0ABT-263\u00a0are\u00a0small\u00a0molecule\u00a0Bcl-2\u00a0inhibitors\u00a0developed\u00a0by\u00a0Abbott\u00a0Laboratories,\u00a0USA.\u00a0ABT-737\u00a0and\u00a0ABT-263\u00a0have\u00a0been\u00a0reported\u00a0to\u00a0bind\u00a0Bcl-2,\u00a0Bcl-xL\u00a0and\u00a0Bcl-w\u00a0(Ki\u00a0&lt;1\u00a0nM)\u00a0with\u00a0high\u00a0affinity,\u00a0and\u00a0the\u00a0binding\u00a0has\u00a0a\u00a0higher\u00a0specificity\u00a0than\u00a0their\u00a0binding\u00a0to\u00a0Mcl-1\u00a0and\u00a0A1\u00a0(two\u00a0other\u00a0anti-apoptotic\u00a0Bcl-2\u00a0proteins)\u00a0.\u00a0In\u00a0addition,\u00a0a\u00a0second\u00a0generation\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0has\u00a0been\u00a0disclosed\u00a0in\u00a0WO\u00a02014/113413\u00a0A1,\u00a0which\u00a0binds\u00a0to\u00a0Bcl-2\u00a0and/or\u00a0Bcl-xL,\u00a0with\u00a0a\u00a0Ki\u00a0value\u00a0of\u00a0&lt;10\u00a0nM,\u00a0and\u00a0functions\u00a0as\u00a0a\u00a0potent\u00a0antagonist\u00a0of\u00a0Bcl-2\u00a0and\u00a0Bcl-xL\u00a0in\u00a0cell-free\u00a0function\u00a0assays.</p>Combination\u00a0therapy\u00a0of\u00a0anti-cancer\u00a0drugs\u00a0is\u00a0sometimes\u00a0used\u00a0in\u00a0the\u00a0treatment\u00a0of\u00a0cancer.\u00a0There\u00a0exists\u00a0needs\u00a0for\u00a0a\u00a0combination\u00a0of\u00a0a\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0having\u00a0high\u00a0anti-cancer\u00a0activity\u00a0and\u00a0low\u00a0side\u00a0effects\u00a0and\u00a0other\u00a0anti-cancer\u00a0agents.</p>SUMMARY\u00a0OF\u00a0INVENTION</p>It\u00a0is\u00a0an\u00a0intent\u00a0of\u00a0the\u00a0present\u00a0disclosure\u00a0to\u00a0provide\u00a0a\u00a0pharmaceutical\u00a0composition\u00a0having\u00a0a\u00a0notable\u00a0anti-cancer\u00a0effect,\u00a0a\u00a0method\u00a0for\u00a0treating\u00a0cancer,\u00a0and\u00a0use\u00a0of\u00a0the\u00a0pharmaceutical\u00a0composition.</p>According\u00a0to\u00a0a\u00a0first\u00a0aspect\u00a0of\u00a0the\u00a0present\u00a0disclosure,\u00a0provided\u00a0herein\u00a0is\u00a0a\u00a0pharmaceutical\u00a0composition\u00a0comprising\u00a0a\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0and\u00a0a\u00a0chemotherapeutic\u00a0agent,\u00a0and\u00a0a\u00a0pharmaceutically\u00a0acceptable\u00a0carrier.\u00a0The\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0is\u00a0a\u00a0compound\u00a0of\u00a0the\u00a0following\u00a0formula\u00a0(I)\u00a0,\u00a0(II)\u00a0,\u00a0(III)\u00a0or\u00a0(IV)\u00a0,\u00a0or\u00a0a\u00a0pharmaceutically\u00a0acceptable\u00a0salt\u00a0thereof:</p><img id=\"\" path=\"PCTCN2019098576-appb-000001.tif\" file=\"https://surechembl.org/api/assets/attachment/657301034/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000001.tif\"/></p><img id=\"\" path=\"PCTCN2019098576-appb-000002.tif\" file=\"https://surechembl.org/api/assets/attachment/657301018/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000002.tif\"/></p>wherein\u00a0the\u00a0A\u00a0ring\u00a0is\n      <img id=\"\" path=\"PCTCN2019098576-appb-000003.tif\" file=\"https://surechembl.org/api/assets/attachment/657301051/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000003.tif\"/>\n    </p",
    "76-appb-000023.tif\" file=\"https://surechembl.org/api/assets/attachment/657301058/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000023.tif\"/></p><img id=\"\" path=\"PCTCN2019098576-appb-000024.tif\" file=\"https://surechembl.org/api/assets/attachment/657301029/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000024.tif\"/></p><img id=\"\" path=\"PCTCN2019098576-appb-000025.tif\" file=\"https://surechembl.org/api/assets/attachment/657301082/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000025.tif\"/></p><img id=\"\" path=\"PCTCN2019098576-appb-000026.tif\" file=\"https://surechembl.org/api/assets/attachment/657301022/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000026.tif\"/></p>The\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0of\u00a0the\u00a0present\u00a0disclosure\u00a0is\u00a0preferably\u00a0(R)\u00a0-2-\u00a0(1-\u00a0(3-\u00a0(4-\u00a0(N-\u00a0(4-\u00a0(4-\u00a0(3-\u00a0(2-\u00a0(4-chlorophenyl)\u00a0-1-isopropyl-5-methyl-4-\u00a0(methylsulfonyl)\u00a0-1H-pyrrol-3-yl)\u00a0-5-fluorophenyl)\u00a0piperazin-1-yl)\u00a0phenyl)\u00a0sulfamoyl)\u00a0-2-\u00a0(trifluoromethylsulfonyl)\u00a0phenylamino)\u00a0-4-\u00a0(phenylthio)\u00a0butyl)\u00a0piperidine-4-carbonyloxy)\u00a0ethylphosphonic\u00a0acid\u00a0(i.e.,\u00a0compound\u00a015,\u00a0in\u00a0the\u00a0above\u00a0table,\u00a0sometimes\u00a0abbreviated\u00a0as\u00a0\"compound\u00a015\"\u00a0)\u00a0or\u00a0a\u00a0pharmaceutically\u00a0acceptable\u00a0salt\u00a0thereof,\u00a0as\u00a0represented\u00a0by\u00a0the\u00a0following\u00a0structural\u00a0formula:</p><img id=\"\" path=\"PCTCN2019098576-appb-000027.tif\" file=\"https://surechembl.org/api/assets/attachment/657301055/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000027.tif\"/></p>Compound\u00a015\u00a0selectively\u00a0binds\u00a0to\u00a0Bcl-2,\u00a0Bcl-xl,\u00a0and\u00a0Bcl-w\u00a0proteins\u00a0with\u00a0high\u00a0affinity,\u00a0and\u00a0has\u00a0an\u00a0IC50\u00a0of\u00a01.6\u00a0nM,\u00a04.4\u00a0nM,\u00a0and\u00a09.3\u00a0nM,\u00a0respectively.\u00a0Compound\u00a015\u00a0binds\u00a0weakly\u00a0to\u00a0Mcl-1.\u00a0Having\u00a0chemical\u00a0structural\u00a0modification,\u00a0Compound\u00a015\u00a0effectively\u00a0reduces\u00a0the\u00a0platelet\u00a0toxicity\u00a0defects\u00a0of\u00a0the\u00a0first-generation\u00a0BCL-2\u00a0inhibitors\u00a0in\u00a0the\u00a0blood\u00a0circulation,\u00a0and\u00a0is\u00a0capable\u00a0of\u00a0inducing\u00a0specific\u00a0enzyme\u00a0activation\u00a0in\u00a0tissues\u00a0to\u00a0effectively\u00a0kill\u00a0tumor\u00a0cells.\u00a0Its\u00a0platelet\u00a0toxicity\u00a0is\u00a0reduced\u00a0by\u00a010-30\u00a0times,\u00a0but\u00a0the\u00a0activity\u00a0is\u00a0about\u00a010\u00a0times\u00a0that\u00a0of\u00a0the\u00a0first\u00a0generation\u00a0BCL-2\u00a0inhibitor.\u00a0Compound\u00a031\u00a0is\u00a0an\u00a0active\u00a0metabolite\u00a0of\u00a0Compound\u00a015.\u00a0Compound\u00a015\u00a0is\u00a0a\u00a0novel\u00a0second\u00a0generation\u00a0protein\u00a0inhibitor\u00a0targeting\u00a0BCL-2.</p>The\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0of\u00a0the\u00a0present\u00a0disclosure\u00a0may\u00a0also\u00a0preferably\u00a0be\u00a0(R)\u00a0-1-\u00a0(3-\u00a0(4-\u00a0(N-\u00a0(4-\u00a0(4-\u00a0(3-\u00a0(2-\u00a0(4-chlorophenyl)\u00a0-1-isopropyl-5-methyl-4-\u00a0(methylsulfonyl)\u00a0-1H-pyrrol-3-yl)\u00a0-5-fluorophenyl)\u00a0piperazin-1-yl)\u00a0phenyl)\u00a0sulfamoyl)\u00a0-2-\u00a0(trifluoromethylsulfonyl)\u00a0phenylamino)\u00a0-4-\u00a0(phenylthio)\u00a0butyl)\u00a0piperidine-4-carboxylic\u00a0acid\u00a0(i.e.,\u00a0compound\u00a031\u00a0in\u00a0the\u00a0above\u00a0table,\u00a0sometimes\u00a0abbreviated\u00a0as\u00a0\"compound\u00a031\"\u00a0)\u00a0or\u00a0a\u00a0pharmaceutically\u00a0acceptable\u00a0salt\u00a0thereof,\u00a0as\u00a0represented\u00a0by\u00a0the\u00a0following\u00a0structural\u00a0formula:</p><img id=\"\" path=\"PCTCN2019098576-appb-000028.tif\" file=\"https://surechembl.org/api/assets/attachment/657301090/WO/20200206/A1/002020/02/49/76/PCTCN2019098576-appb-000028.tif\"/></p>The\u00a0above\u00a0Bcl-2/Bcl-xL\u00a0inhibitor\u00a0of\u00a0the\u00a0pharmaceutical\u00a0composition\u00a0of\u00a0the\u00a0present\u00a0disclosure\u00a0can\u00a0be\u00a0synthesized\u00a0according\u00a0to\u00a0the\u00a0method\u00a0described\u00a0in\u00a0WO2014/113413A1.</p>Chemotherapeutic\u00a0Ag"
]